Barclays
EDIT icon

Barclays’s Editas Medicine EDIT Stock Holding History

Barclays’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,900
Closed -$68K – 7183
2018
Q2 		$68K Buy
+1,900
New +$67.3K ﹤0.01% 5471

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Barclays's EDIT Position: Q2 2026 in Review

Barclays increased its Editas Medicine (EDIT) stake by 2.5% in Q2 2026, buying an estimated $10.7K and bringing the position to 149,264 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #3252.

Barclays first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $4.39M in Q1 2021. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Barclays held 149,264 shares of Editas Medicine worth $484K as of Q2 2026.
  • Barclays bought 3,662 Editas Medicine shares in Q2 2026, an estimated $10.7K.
  • Editas Medicine made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3252 holding.
  • Barclays first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • Barclays's Editas Medicine position peaked at $4.39M in Q1 2021.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.